Strategic Immunotherapy Funding Tactiva has secured significant early-stage grant support ($23M) from NCI SPORE and NYSTEM, signaling validated potential and opportunities for non-dilutive funding conversations or partnerships for co-development or translational research collaborations.

Series A Momentum Recent $35M Series A financing indicates investor confidence and a readiness to scale, presenting a doorway for strategic partnerships, licensing discussions, and potential enterprise collaborations around manufacturing, process development, or expanded clinical programs.

Licensed Tech Advantage The dual TCR adoptive T cell therapy approach is licensed from Roswell Park, offering a clear technology moat and potential for collaboration in license-in opportunities, joint development arrangements, or access to RPCI-backed data and networks.

Early Stage Focus With a small team (2-10 employees) and revenue in the zero to one million range, there are opportunities to engage in early-stage service partnerships, contract research, or feasibility collaborations that align with their immuno-oncology pipeline.

Buffalo Biotech Access Headquartered in Buffalo, NY, Tactiva can be positioned for regional government and academic partnerships, talent acquisition initiatives, and regional grant programs, offering sales angles around biofabrication, GMP readiness, and translational science collaborations.